advanced carcinoma
Conditions
Interventions
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Histologically confirmed metastasized cancer and planned treatment with weekly paclitaxel Women Written informed consent Age >= 18 years
Exclusion criteria
Exclusion criteria: Boldness prior to treatment of the study Serious psychiatric illness, confusion or intellectual disability Hematologic malignancy Cold sensitivity, cold agglutinin disease, cryoglobulinemia, cold post-traumatic dystrophy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in pharmacokinetics of paclitaxel (AUC, e.g. the exposure to paclitaxel in blood) between patients who undergo scalp cooling during their anti-cancer treatment versus those patients, who did not undergo scalp cooling during their anti-cancer treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in pharmacokinetics of paclitaxel (AUC, e.g. the exposure to paclitaxel in blood) between patients who do and who do not develop boldness during the use of scalp cooling and their anti-cancer treatment. If this is clinically relevant, other pharmacokinetic parameters will be studied, such as clearance. | — |
Countries
The Netherlands
Outcome results
None listed